LianBio (LIAN) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:LIANLianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
(0.6)
LianBio Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Price to Book (PBV) RatioUndervalued price-to-book. LIAN stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)LIAN equity is higher than it's debt. |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthLIAN has never had growing revenue. |
|
Net Income GrowthLIAN has never had growing net income. |
|
Net IncomeLIAN never has positive net income for 2 years. |
|
Dividend YieldLIAN has low dividend yield (0%). |
|
Return of AssetsLIAN has low return of asset (-78.22%). |
|
Return of EquityLIAN has low return of equity (-88.08%). |
|
RevenueLIAN never has positive revenue for 2 years. |
|
Return of Invested CapitalLIAN has low ROIC. |
Competitors
LianBio Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 0 USD
- Net Income
- -196,300,000 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -164,900,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 1458.27% |
Long Term Liabilities
| Liquidity/Current Ratio | 1472% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -0.5x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 1472% |
| Cash Ratio | 358.02% |
| Debt Ratio | 12.86% |
| Debt-Equity Ratio (DER) | 16.58% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -78.22% |
| Return of Equity (ROE) | -88.08% |
| Return on Capital Employed (ROCE) | -35.82% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
LianBio Executives
CEO
- CEO Name
Management
LianBio Profile
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Additional Information
- Company name
- LianBio
- Symbol
- NASDAQ:LIAN
- Exchange
- NASDAQ Global Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
103 Carnegie Center Drive
Princeton
NJ
US
08540 - Website
- https://www.lianbio.com